Paul Chaney

Paul G. Chaney is Co-Founder, President & CEO of PanOptica Inc., a biopharma company developing PAN-90806, a novel topical anti-VEGF treatment for neovascular eye diseases. Prior to founding PanOptica, Paul was EVP & President of (OSI) Eyetech. At Eyetech, Paul served as COO and was responsible for the launch of Macugen, the first anti-VEGF treatment for neovascular age-related macular degeneration (wet-AMD). Paul has over 30 years of experience in the pharmaceutical industry, including a variety of senior management positions at Pharmacia Corporation where he launched Xalatan (latanoprost) and Xalcom, (latanoprost/timolol) leading treatments for glaucoma.